Fig. 3

CPA selectively up-regulates DR5 expression in prostate cancer cells. DU145 cells were treated with 50 μM CPA for the indicated time a or indicated concentrations of CPA for 12 h b. Cells were harvested and subjected to western blot analysis. Data shown are means ± S.E. (n = 3) with **p < 0.01. β-actin was used as a loading control and the indicated protein level in control cells without CPA treatment was normalized as one. (a, left panel) and (b, inset): Representative western blot images of indicated proteins. c DU145 cells were pretreated without or with 50 μM CPA for 24 h, and then treated with 50 μM cycloheximide for 10 min (time = 0). Cells were harvested at indicated times and subjected to western blot analysis. Data shown are means ± S.E. (n > 3) with **p < 0.01. DR5 protein levels at 0 h were set as one. Inset: Representative western blot images of DR5 and β-actin. d and e DU145 cells were treated with 50 μM CPA for the indicated time d or indicated concentrations of CPA for 6 h e. DR4 and DR5 mRNA levels were determined by quantitative RT-PCR analysis. β-actin was used as an internal control. Data shown are means ± S.E. (n = 3) with *p < 0.05